Johnson & Johnson Develops Novel RYBREVANT® for EGFR-Mutated Advanced Lung Cancer
Johnson & Johnson has introduced a groundbreaking therapy, RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE™ (lazertinib), for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or exon 21 L858R substitution mutations.
RYBREVANT® is a bispecific antibody targeting both EGFR and MET*, designed to engage the immune system, while LAZCLUZE™ is a highly selective, brain-penetrant, third-generation oral EGFR TKI**. This combination therapy is the first multitargeted regimen that directly addresses the most common EGFR mutations.
This approval marks a significant advancement for patients with EGFR-mutated NSCLC, a group that has long faced substantial unmet medical needs.
Lung cancer remains the leading cause of cancer-related deaths globally, with 1.8 million fatalities annually. NSCLC accounts for 80 to 85 percent of these cases. Among patients with EGFR-mutated NSCLC, 25 to 39 percent never receive second-line therapy due to disease progression and limited treatment options.
The five-year survival rate for those with advanced EGFR-mutated NSCLC treated with the current standard of care TKI monotherapy remains below 20 percent.
The MARIPOSA study demonstrated that the combination of RYBREVANT and LAZCLUZE offers superior efficacy in the first-line treatment of patients with advanced EGFR-mutated NSCLC.
